arrow
M

Melyssa Aronson

Sinai Health System
H指数:44
被引数:8,987

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma

错配修复缺陷型神经胶质瘤的高突变形状肿瘤发生和免疫治疗反应的模式

2025-12-220
PRE
Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens

机会性筛查对广泛相关的临床二级发现的实验室效益与负担

2025-10-140
OAAI
Opportunistic genomic screening has clinical utility: An interventional cohort study

机会性基因组筛查具有临床应用价值:一项干预性队列研究

2025-02-010
PRE
A Validated Highly Sensitive Microsatellite Instability Assay Accurately Identifies Individuals Harboring Biallelic Germline PMS2 Pathogenic Variants in Constitutional Mismatch Repair Deficiency

经过验证的高度敏感的微卫星不稳定性分析可准确识别在体质错配修复缺陷中携带双等位基因种系PMS2致病性变异的个体

2024-03-261
OA
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium

联合免疫疗法可改善Anti-PD-1单一疗法失败的复制修复缺陷 (RRD) 高级别神经胶质瘤的结果: 来自国际RRD联盟的报告

2023-10-1212
OAAI
THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A REPORT FROM THE IRRDC AND THE GLIOMA TASK FORCE.
2023-06-120
OAAI
A model for the return and referral of all clinically significant secondary findings of genomic sequencing
2023-05-224
PRE
Development of a comprehensive approach to adult hereditary cancer testing in Ontario

在安大略省开发成人遗传性癌症检测的综合方法

2022-12-233
PRE
A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings
2022-06-232
PRE
A comprehensive genomic test reporting structure for communicating cancer and incidental findings
2022-03-010
OA
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

生殖系DNA复制修复缺陷儿童对PD-1抑制反应的基因组预测因子

2022-01-0672
OAAI
Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer
CANCER
IF5.1
2021-05-138
OAAI
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
2021-02-0926
OA